Fig. 2: T-cell activation by epcoritamab does not correlate strongly with cytotoxic activity. | Blood Cancer Journal

Fig. 2: T-cell activation by epcoritamab does not correlate strongly with cytotoxic activity.

From: Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Fig. 2

A Gating of CD4+ and CD8+ cells and example of a flow histogram for CD69 positivity and B percentages of CD69-positive CD4+ and CD8+ allogeneic T-cells after treatment of B-NHL samples with epcoritamab and CD3xCtrl (30 ng/mL) (median ± interquartile range). C Granzyme B levels (pg/mL) in supernatants of coculture of B-NHL sample and allogeneic T-cells stimulated with epcoritamab and CD3xCtrl (30 ng/mL) (median ± interquartile range). D, E Correlation between percentage CD69-positive (CD4+ and CD8+) allogeneic T-cells (D) or granzyme B release (pg/mL) (E), and cytotoxicity induced by epcoritamab (30 ng/mL) (Spearman’s; ns and r = 0.35; *p = 0.04, respectively). All samples from different B-NHL subtypes and from ND and RR are plotted together.

Back to article page